This week we take a look at the latest buzz in the pharmaceutical realm. We’ve got mind-blowing results from a study on a secret weapon against a pesky skin condition known as Hidradenitis Suppurativa, the potential green light for brand-new RSV vaccines from GSK & Pfizer, some bad news for diabetes patients with AstraZeneca discontinuing its diabetes medicine trials, and other top news!
A recent study conducted by a union of researchers has shown promising results for the use of oral orismilast in patients with hidradenitis suppurativa (HS). HS is a chronic inflammatory skin condition, and current treatment options are limited. The study found that patients who received oral orismilast experienced a significant reduction in disease severity and improvement in quality of life. These findings suggest that oral orismilast could be a potential treatment option for HS patients, offering hope for improved management of this challenging condition.
The Advisory Committee on Immunization Practices (ACIP) is preparing to vote on the use of new respiratory syncytial virus (RSV) shots developed by GlaxoSmithKline (GSK) and Pfizer. RSV is a common respiratory infection that can be severe, especially in infants and older adults. The new shots aim to provide protection against RSV and potentially reduce the burden of the disease. The upcoming vote by the ACIP panel will determine whether these new RSV shots will be recommended for use, potentially shaping future immunization strategies.
Coherus Biosciences, a biopharmaceutical company focused on biosimilar products, has announced the acquisition of a new asset for $65 million. This move marks Coherus’ expansion into new therapeutic areas beyond biosimilars. The acquired asset is a novel therapy with potential applications in multiple disease areas. By diversifying its portfolio, Coherus aims to leverage its expertise and expand its presence in the pharmaceutical market, offering innovative treatment options to patients and further establishing itself as a key player in the industry.
The U.S. Food and Drug Administration (FDA) has granted approval to Agepha Pharma’s heart disease drug. This medication offers a new treatment option for patients with heart disease, a leading cause of death globally. The drug has undergone rigorous clinical trials, demonstrating its safety and efficacy in reducing the risk of cardiovascular events. With the FDA’s green light, Agepha Pharma can now make this important therapy available to patients, potentially improving outcomes and addressing the unmet medical needs in the field of heart disease.
AstraZeneca has decided to discontinue the development of its GLP-1 drug for diabetes after facing a setback in Phase 1 clinical trials. GLP-1 drugs are commonly used to manage blood sugar levels in patients with type 2 diabetes. Unfortunately, the results from the Phase 1 trials did not meet the desired endpoints, leading to the discontinuation of further development. This decision is a disappointment for AstraZeneca and the diabetes community, as they had hoped for a new treatment option to enhance diabetes management.
Exclusive Sponsor: Axtria – the leading global provider of cloud software and data analytics solutions to the life sciences industry.